Tumor-associated glycolipid

Cancer-associated cell-surface glycan–lipid signatures refer to the aberrant patterns of glycolipids and glycosphingolipids expressed on the plasma membrane of malignant cells. These signatures, often termed tumor-associated carbohydrate antigens (TACAs), result from altered glycosylation pathways during oncogenesis, leading to the over-expression of specific molecules like gangliosides (e.g., GD2, GD3) and globo-series glycans (e.g., Globo H) [1][2]. These molecules play critical roles in modulating cell signaling, promoting cell-cell adhesion, and facilitating immune evasion by interacting with inhibitory receptors on immune cells [3]. Because these signatures are often highly enriched on tumor surfaces compared to normal tissues, they serve as attractive targets for monoclonal antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies [4]. Clinical examples include the targeting of GD2 in neuroblastoma and Globo H in various epithelial cancers, though challenges such as neurotoxicity and low carbohydrate immunogenicity remain significant hurdles in drug development [5][6].

Other names

Cancer-associated cell-surface glycan–lipid signaturesTumor-associated carbohydrate antigensTACAsCancer-associated glycosphingolipidsTumor-associated gangliosides

Therapeutic agents target these signatures to induce antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or to trigger an active immune response through vaccination, thereby selectively destroying tumor cells expressing these aberrant glycan-lipid complexes.